RYSTIGGO DIN 02556081
Status: Marketed
Holder: UCB CANADA INC
Health Canada record
| Active ingredient(s) | ROZANOLIXIZUMAB 280 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AL02 ROZANOLIXIZUMAB |
|---|
| Original market date | 05-Sep-2025 |
|---|
| Current status date | 05-Sep-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
UCB Canada Inc — licence 101597, currently licensed, last inspection rating C (2024-11-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ROZANOLIXIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02567067 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 420 MG | Approved |
| 02567075 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 560 MG | Approved |
| 02567083 | RYSTIGGO | UCB CANADA INC | Solution | ROZANOLIXIZUMAB 840 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 35243 | 2025-04-25 | New Drug Submission (NDS) | |
Request a quote for RYSTIGGO
How to read a Canadian DIN record